Latham & Watkins advised Owlet in the offering, and DLA Piper advised Titan Partners Group, as underwriter. Owlet, Inc. (NYSE:OWLT), the pioneer of smart infant monitoring,...
Owlet’s $11.6 Million Common Stock Offering
Illumina’s Divestiture of GRAIL
Cravath, Swaine & Moore represented Illumina, Inc. on the transaction, and Latham & Watkins represented GRAIL, LLC. GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare...
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
Alignment Healthcare’ $250 Million Debt Financing
Latham & Watkins represented Alignment Healthcare in the transaction. Alignment Healthcare, Inc.(Alignment Healthcare) (NASDAQ: ALHC), a leading tech-enabled MedicareAdvantage company, has announced the close of an...
Arcutis Biotherapeutics’ $150 Million Shares Offering
Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten...
Horizon Technology Finance Corporation’s $45 Million Growth Facility in InBrace
Latham & Watkins LLP represented InBrace in the transaction. Horizon Technology Finance Corporation (NASDAQ: HRZN) (Horizon) has announced the close of a US$45 million growth facility...
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
Traeger’s $487 Million Initial Public Offering
Latham & Watkins LLP represented Traeger, while Fried Frank acted as counsel to Morgan Stanley & Co. LLC, as representative of the underwriters, in the IPO....